Brenda Hefti Sells 6,625 Shares of Exelixis (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) SVP Brenda Hefti sold 6,625 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $50.21, for a total value of $332,641.25. Following the transaction, the senior vice president directly owned 106,762 shares of the company’s stock, valued at approximately $5,360,520.02. The trade was a 5.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Brenda Hefti also recently made the following trade(s):

• On Wednesday, February 18th, Brenda Hefti sold 18,669 shares of Exelixis stock. The shares were sold at an average price of $44.01, for a total value of $821,622.69.

Exelixis Trading Up 2.5%

Shares of Exelixis stock opened at $49.90 on Thursday. The stock has a 50 day moving average of $44.77 and a 200 day moving average of $43.72. Exelixis, Inc. has a 12 month low of $33.76 and a 12 month high of $51.63. The firm has a market cap of $12.54 billion, a PE ratio of 16.58, a PEG ratio of 1.03 and a beta of 0.38.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.12. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The company had revenue of $610.81 million during the quarter, compared to analyst estimates of $607.51 million. During the same period in the prior year, the company earned $0.55 earnings per share. The firm’s revenue was up 10.0% on a year-over-year basis. As a group, equities research analysts forecast that Exelixis, Inc. will post 3.15 earnings per share for the current fiscal year.

Key Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Exelixis announced a clinical development collaboration with Merck for the phase III STELLAR-316 colorectal cancer trial, pairing zanzalintinib with Merck’s KEYTRUDA-based subcutaneous therapy. The deal expands Exelixis’s pipeline beyond Cabometyx and gives the market another potential growth driver. Article Title
• Positive Sentiment: Management also highlighted strong momentum around Cabometyx during the Q1 earnings call, reinforcing confidence that the company’s core cancer franchise remains healthy and continues to support revenue growth. Article Title
• Neutral Sentiment: Exelixis presented at the Stifel 2026 Targeted Oncology Virtual Forum and RBC Capital Markets Global Healthcare Conference, which likely kept the company visible to investors but did not appear to include a major new catalyst. Article Title
• Negative Sentiment: Recent insider sales by CFO Christopher Senner and SVP Brenda Hefti may have slightly tempered enthusiasm, although both transactions were disclosed as part of pre-arranged 10b5-1 trading plans and are not necessarily a bearish signal. Article Title

Institutional Investors Weigh In On Exelixis

Several hedge funds and other institutional investors have recently modified their holdings of EXEL. AQR Capital Management LLC raised its holdings in shares of Exelixis by 48.8% in the fourth quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock worth $598,647,000 after buying an additional 4,477,029 shares during the period. Farallon Capital Management LLC raised its holdings in shares of Exelixis by 21.6% in the third quarter. Farallon Capital Management LLC now owns 19,501,500 shares of the biotechnology company’s stock worth $805,412,000 after buying an additional 3,466,000 shares during the period. Assetmark Inc. raised its holdings in shares of Exelixis by 1,230.8% in the third quarter. Assetmark Inc. now owns 3,195,971 shares of the biotechnology company’s stock worth $131,994,000 after buying an additional 2,955,813 shares during the period. Norges Bank purchased a new stake in shares of Exelixis in the fourth quarter worth approximately $106,460,000. Finally, Allianz Asset Management GmbH raised its holdings in shares of Exelixis by 153.3% in the third quarter. Allianz Asset Management GmbH now owns 2,462,948 shares of the biotechnology company’s stock worth $101,720,000 after buying an additional 1,490,520 shares during the period. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Royal Bank Of Canada decreased their price objective on Exelixis from $46.00 to $43.00 and set a “sector perform” rating on the stock in a research report on Monday, March 2nd. Barclays upped their price objective on Exelixis from $44.00 to $45.00 and gave the company an “equal weight” rating in a research report on Monday, April 20th. TD Cowen upped their price objective on Exelixis from $51.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Wall Street Zen upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Zacks Research downgraded Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 5th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Exelixis has a consensus rating of “Hold” and an average price target of $47.35.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.